The global “dermatology drugs market” size is expected to USD 63.99 billion by 2027, exhibiting a CAGR of 12.9% during the forecast period. The increasing prevalence of numerous skin diseases and disorders among the population is expected to spur opportunities for the market, states Fortune Business Insights, in a report, titled “Dermatology Drugs Market Size, Share & Industry Analysis, By Application (Acne, Psoriasis, Atopic Dermatitis, and Others), By Route of Administration (Oral, Parenteral, and Topical) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The market size stood at USD 36.82 billion in 2019.

The occurrence of coronavirus has exerted massive economic stress on sectors in various countries. We understand that this health emergency has negatively impacted various sectors across the globe. Rising support from governments and several companies can help in the fight against this highly infectious virus. There are some industries that are struggling and some are thriving. More or less, nearly every sector is estimated to be impacted by this pandemic.

We are perpetually working on our reports to help uplift businesses in this crucial time. Our expertise and experience can offer enormous benefits to help regain during this global pandemic. 

Major Dermatology Drugs Market Key players covered in the report include:

  • Allergan (Dublin, Ireland)
  • Botanix Dermatology Drugs (NorthBridge, Australia)
  • Pfizer Inc. (New York, U.S)
  • Galderma S.A (Lausanne, Switzerland)
  • Bausch Health Companies Inc. (Bridgewater, U.S)
  • Novartis (Switzerland, Europe)
  • GlaxoSmithKline Plc. (London, U.K)
  • Valeant Dermatology Drugs International Inc. (New Jersey, U.S)
  • Johnson & Johnson (New Jersey, U.S)
  • Other Players

Get Request a Sample Copy of the Dermatology Drugs Report:

https://www.fortunebusinessinsights.com/enquiry/sample/dermatology-drugs-market-104432

Our research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers and acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.

It offers figurative estimations for upcoming years on the basis of the recent developments and historic data. For gathering information and estimating revenue for all segments, researchers have used top-down and bottom-up approaches. On the basis of data collected from primary and secondary research and trusted data sources the report will help both existing and new aspirants for market to figure out and study the market’s needs, market size, and competition.

Dermatology Drugs Market Analysis 2021:

Market Driver:

Surging Patient Population to Back Growth

The growing number of patients suffering from acne, vitiligo, and dermatitis are expected to spur opportunities for market growth. According to the American Association of Dermatology in 2018, around 50 million people in the U.S had acne. The growing demand for effective products to cure skin infections and disorders coupled with high awareness among the young population will contribute positively to the growth of the market. According to Australian research, more than 4% of the population are affected by acne vulgaris in long term. The growing inclination towards skin health and care among millennials can have an excellent impact on the market growth in the forthcoming years. The increasing R&D investments by major companies owing to heavy demand for therapeutically effectual and cost-effective drugs will encourage the healthy growth of the market in the foreseeable future.

Diminished Demand for Dermatology Drugs to Impede Market amid COVID-19

The COVID-19 pandemic has critically impacted the global market because of the weakened demand for dermatology drugs. Pharmaceutical companies producing skin-related drugs experienced massive losses owing to the lockdown imposed by governments. Thus, leading to disrupted supply and demand. Social distance regulations coupled with lower demand for mandatory prescribed dermatology medications will further restrict the growth of the market. According to the American Association of Dermatology, the dermatologists in the U.S reported an approximately 43% decline in patient consultations during the pandemic crisis. In addition, declining production and demand will simultaneously affect market sales during the coronavirus pandemic.

For more information visit : 

https://www.fortunebusinessinsights.com/dermatology-drugs-market-104432